Literature DB >> 28128060

Proteoglycans and Diabetes.

Linda M Hiebert1.   

Abstract

BACKGROUND: Most proteoglycans are heterogeneous molecules composed of a protein core with glycosaminoglycans (GAGs) attached. GAGs are highly negatively charged molecules that readily bind to enzymes, growth factors, cytokines etc. and as such have many functions. The role played by proteoglycans in diabetes has only recently been investigated.
METHODS: The importance of proteoglycans and the effects of diabetes on proteoglycans are discussed. Possible strategies for reducing diabetic complications associated with preventing proteoglycan destruction are examined.
RESULTS: Proteoglycans are altered in the endothelium, vascular wall, kidney, retina, heart, gut epithelial cells, bone and cartilage with diabetes. A decrease in proteoglycans, associated with hyperglycemic conditions, is reported to be due to a decrease in proteoglycan synthesis or an increase in destruction. Destruction may be a result of an upregulation of enzymes that degrade GAGs or destruction by reactive oxygen species. Several studies suggest that upregulation of heparanase and its destruction of heparan sulfate proteoglycans may be responsible for many of the complications associated with diabetes particularly in the kidney and blood vessels leading to chronic kidney disease, atherosclerosis and acute coronary syndrome. Preliminary studies suggest that administration of GAGs may be beneficial in reducing or delaying the harmful consequences of diabetes in the kidney and retina.
CONCLUSIONS: Changes in proteoglycans are partially responsible for diabetic complications. Recent studies demonstrate that administration of GAGs may reduce or delay diabetic complications. Further studies are required to understand the alterations in proteoglycans associated with diabetes, and the protective potential of administered GAGs. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Diabetes; acute coronary syndrome; endothelium; heparan sulfate proteoglycans; heparanase; kidney; reactive oxygen species; retina

Mesh:

Substances:

Year:  2017        PMID: 28128060     DOI: 10.2174/1381612823666170125154915

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

1.  Evidence of glucuronidation of the glycation product LW-1: tentative structure and implications for the long-term complications of diabetes.

Authors:  David R Sell; Ina Nemet; Zhili Liang; Vincent M Monnier
Journal:  Glycoconj J       Date:  2018-01-05       Impact factor: 2.916

2.  Distinct osmoregulatory responses to sodium loading in patients with altered glycosaminoglycan structure: a randomized cross-over trial.

Authors:  Eliane F E Wenstedt; Jetta J Oppelaar; Stijn Besseling; Nienke M G Rorije; Rik H G Olde Engberink; Arie Oosterhof; Toin H van Kuppevelt; Bert-Jan H van den Born; Jan Aten; Liffert Vogt
Journal:  J Transl Med       Date:  2021-01-20       Impact factor: 5.531

Review 3.  Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.

Authors:  Antony Cheudjeu
Journal:  Life Sci       Date:  2020-08-23       Impact factor: 5.037

4.  Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer's disease associated with obesity, metabolic syndrome, and type 2 diabetes.

Authors:  Maria Elizabeth De Sousa Rodrigues; Madelyn C Houser; Douglas I Walker; Dean P Jones; Jianjun Chang; Christopher J Barnum; Malú G Tansey
Journal:  Alzheimers Res Ther       Date:  2019-12-31       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.